MarketBeat
11 Aug 2026, 05:02 UTC · 1h ago
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
11 Aug 2026, 05:02 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The Phase II SANRECO trial of divesiran met its primary endpoint, with 88% of treated patients maintaining hematocrit below 45% without phlebotomy compared to 18% for placebo. — Strong clinical efficacy with high statistical significance (p < 0.0001) significantly increases the probability of regulatory success for a core asset.
+0.80Divesiran showed a strong safety profile with no new safety issues identified and only infrequent, mild injection-site reactions. — Lack of unexpected adverse events reduces the clinical risk profile and smooths the path toward Phase III trials.
+0.50Silence Therapeutics plans to advance a quarterly (every-12-week) dosing regimen into a Phase III registration trial starting in the first half of 2027. — Establishes a clear regulatory roadmap and a competitive commercial advantage through infrequent dosing.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The trial demonstrated a substantial reduction in phlebotomy burden, with over 90% of treated patients requiring no phlebotomies versus 12.5% of placebo patients. — This provides a tangible quality-of-life improvement that differentiates the drug from current standard care.
+0.30Which stocks this story touches
The company reported positive Phase II trial results for divesiran, meeting its primary endpoint with high response rates and a strong safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
6h ago
